MEDIROM Healthcare Technologies (ADR) (MRM)
Japanese relaxation-salon network operator with health guidance, monitoring, beauty, rehabilitation, and identity-verification services.
MEDIROM MOTHER Labs Expands Deployment of "REMONY®" Remote Health Monitoring System in JGSDF 8th Division
Additional Orders Triple Implementation Scale; "MOTHER Bracelet®" Enables Continuous Safety Monitoring During Extended Training Additional Orders Triple Implementation Scale; "MOTHER Bracelet®" Enables Continuous Safety Monitoring During Extended Training
MEDIROM Group Reports Q1 2026 Results
TOKYO, May 28, 2026 (GLOBE NEWSWIRE) -- This report presents an overview of our business performance and key performance indicators (KPIs) for the first quarter of 2026 (January–March 2026). It also highlights trends over the past five quarters (2025Q1–2026Q1) to provide investors with a broader perspective. Data includes salons with comparable financial and customer metrics.
Medirom Healthcare Technologies (NASDAQ:MRM) Shares Down 2.4% – Here’s What Happened
Medirom Healthcare Technologies Inc. (NASDAQ: MRM - Get Free Report)'s share price fell 2.4% during mid-day trading on Thursday. The company traded as low as $1.23 and last traded at $1.23. 8,330 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 906,670 shares. The stock had previously closed
MEDIROM Launches Partnership with Tools for Humanity in February; Projects Approximately $39 Million in Income Before Income Taxes Over Two Years Following Expansion to 3,000 Nationwide Locations
TOKYO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Kouji Eguchi; listed on the Nasdaq Capital Market: NASDAQ: MRM) announced that the Master Service Agreement (the “Agreement”) entered into with Tools for Humanity (co-founded by Sam Altman and Alex Blania) and World Foundation became effective on February 2, 2026.
MEDIROM Healthcare Technologies (NYSE:MRM) Shares Down 2.7% – What’s Next?
Shares of MEDIROM Healthcare Technologies Inc. (NYSE: MRM - Get Free Report) were down 2.7% on Tuesday. The stock traded as low as $1.7650 and last traded at $1.80. Approximately 48,139 shares were traded during mid-day trading, a decline of 41% from the average daily volume of 82,024 shares. The stock had previously closed at
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
ESCONDIDO, Calif.--(BUSINESS WIRE)--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). MRM-3379 is an orally available, highly brain-penetrant, selective phosphodiestera.
World, Co-founded by Sam Altman and Alex Blania, Accelerates Expansion in Japan via MEDIROM Collaboration Re.Ra.Ku's “Orb” Authentication Surpasses 20,000 Cumulative Verifications, Doubling in Approximately Two Months
TOKYO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM, MEDIROM or the “Company”), announces that the cumulative number of Proof of Human authentications using the World ID authentication device ‘Orb' at stores centered on the relaxation salon “Re.Ra.Ku,” operated by its subsidiary MEDIROM Wellness Co., surpassed 20,000 as of December 28, 2025.
Financial Contrast: Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)
Regis (NASDAQ: RGS - Get Free Report) and Medirom Healthcare Technologies (NASDAQ: MRM - Get Free Report) are both small-cap services companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations. Volatility and Risk Regis has a beta
Comparing Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)
Medirom Healthcare Technologies (NASDAQ: MRM - Get Free Report) and Regis (NASDAQ: RGS - Get Free Report) are both small-cap services companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk. Insider and Institutional Ownership 31.5% of Regis
Analyzing Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)
Medirom Healthcare Technologies (NASDAQ: MRM - Get Free Report) and Regis (NASDAQ: RGS - Get Free Report) are both small-cap services companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation. Profitability This table compares Medirom Healthcare Technologies
Critical Analysis: Medirom Healthcare Technologies (NASDAQ:MRM) vs. Regis (NASDAQ:RGS)
Medirom Healthcare Technologies (NASDAQ: MRM - Get Free Report) and Regis (NASDAQ: RGS - Get Free Report) are both small-cap services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Volatility and Risk Medirom Healthcare Technologies has
MEDIROM Partners with World
TOKYO, Dec. 26, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters:Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM, MEDIROM or the "Company"), a diversified healthcare company, is collaborating with World Foundation and Tools for Humanity to deploy Proof of Human technologies such as World ID throughout Japan.
Medirom Healthcare Technologies (NASDAQ:MRM) vs. Regis (NASDAQ:RGS) Head-To-Head Analysis
Regis (NASDAQ: RGS - Get Free Report) and Medirom Healthcare Technologies (NASDAQ: MRM - Get Free Report) are both small-cap services companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Risk and Volatility Regis has a beta
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). Caused by a mutation of the FMR1 gene, FXS is the most common inherited form of intellectual disability and autism spectrum disorder and affects an estimated 50,000 males in the U.S. and E.U. There are currently no approved therapies for t.
MEDIROM MOTHER Labs Inc. Receives Capital Investment from Internal Investors
Completion of Private Placement of New Shares as Part of Series A Round Valued at ¥9 Billion Completion of Private Placement of New Shares as Part of Series A Round Valued at ¥9 Billion
Japan Ground Self-Defense Force Adopts MEDIROM MOTHER Labs' REMONY for Advanced Health Monitoring and Heatstroke Safety
TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM MOTHER Labs Inc. (“MOTHER Labs”), has begun providing its remote health monitoring system “REMONY,” powered by the recharge-free smart tracker MOTHER Bracelet® , to the Japan Ground Self-Defense Force (JGSDF). ■Background of the Deployment
Ackermans & van Haaren supports MRM Health's Series B financing round of 55 million euros
Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren (AvH) supports the Series B financing round totaling 55 million euros of MRM Health, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology. For AvH, this series B financing round involves an additional investment of 3 million euros and brings its total investment in MRM Health to 10.8 million euros and its fully diluted participation to 14.1%.
MEDIROM launches cryptocurrency strategy with next-generation proof of human technology, "World"
TOKYO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM) (the “Company”, “we” or “us”), which operates a diversified healthcare business, announced its participation in “World,” a “proof of human” protocol co-founded by Sam Altman and Alex Blania. The purpose of this project is to build a new digital infrastructure that will enable "proof of humanness" in the age of AI.
MEDIROM Joins the World Network, Embracing Next-Generation Proof of Human Concept Led by ChatGPT Creator Sam Altman
Creating new social infrastructure in collaboration with Hakuhodo To promote the spread of World ID in Japan, Verification Device“Orb”will be installed in 100 Re.Ra.Ku relaxation salons.
MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements
MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements. The Company's ADSs had been $1.00 per share or greater.